The group has over 20 years of experience in clinical and translational research on Alzheimer’s disease. The main scientific interest is the use of neuroimaging techniques and other biomarkers in persons with or at risk for cognitive impairment. Acquisitions and innovations in fundamental neurosciences, ICT, and technology are uptaken and translated for use into a clinical setting for better pathophysiological understanding, diagnosis, prognosis, disease tracking, drug therapy, and rehabilitation. Specific topics of investigation are: the clinical use of imaging and fluid biomarkers; in vivo neurobiology of Alzheimer’s disease; the clinical use of innovative PET ligands; harmonisation of imaging markers for clinical use; development of innovative image analysis environments based on advanced ICT technology.
Comparison of visual criteria for amyloid-PET reading: could their merging reduce the inter-raters variability?
Primary fatty amides in plasma associated with brain amyloid burden, hippocampal volume, and memory in the European Medical Information Framework for Alzheimer's Disease biomarker discovery cohort.
Inflammatory biomarkers in Alzheimer's disease plasma.
Whole-brain microstructural white matter alterations in borderline personality disorder patients.
Département de psychiatrie